Chief Financial Officer (8) · ORAMED PHARMACEUTICALS INC. (ORMP)

David Silberman

A named executive officer of ORAMED PHARMACEUTICALS in every fiscal year CompBrief holds from FY2021 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$536,711

Salary $156,070Stock awards $277,180Bonus $62,027

FY2022: $1,269,200

4th of 4 named executive officers at Oramed Pharmaceuticals by FY2023 total.

4 named officers on file for ORAMED PHARMACEUTICALS, FY2023

David Silberman’s pay file — $29

  • 3 fiscal years of pay, line by line
  • ORMP’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ORAMED PHARMACEUTICALS’s whole pay program stands against its peers

  • ORAMED PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ORMP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 20, 2024 (DEF 14A).

Free

Get David Silberman’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

David Silberman compensation by year

ORAMED PHARMACEUTICALS Summary Compensation Table · all 3 fiscal years held
In US dollars, as ORAMED PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023
Salary$27,762$155,125$156,070
Bonus$0$49,732$62,027
Stock awards$0$759,405$277,180
Option awards$0$261,754$0
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$4,376$43,184$41,434
Total$32,138$1,269,200$536,711

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ORAMED PHARMACEUTICALS INC. DEF 14A filed June 20, 2024, accession 0001213900-24-054007, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ORAMED PHARMACEUTICALS INC. filed document, accession 0001213900-24-054007. Every figure is read from that document and cited to the page and table it appears in. Filed June 20, 2024.

$32K
$1.3M
$537K
FY21
FY22
FY23
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU176,375$407,426—
Option25,000—$20.19
Option24,000—$13.89
Option2,374—$3.91

Per the Outstanding Equity Awards at Fiscal Year-End table in ORAMED PHARMACEUTICALS INC.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

ORAMED PHARMACEUTICALS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Nadav KidronPresident, Chief Executive Officer and Chairman$1,659,222
Miriam KidronChief Scientific Officer and director$1,109,431
Joshua HexterChief Operating & Business Officer$728,440
David Silberman · this pageChief Financial Officer (8)$536,711

The full ORAMED PHARMACEUTICALS compensation record

free company brief

This page is one person within ORAMED PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ORAMED PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ORAMED PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

David Silberman's compensation dossier · One-time report. No refunds.